TY - JOUR
T1 - The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention
AU - Altice, Frederick L.
AU - Sullivan, Lynn E.
AU - Smith-Rohrberg, Duncan
AU - Basu, Sanjay
AU - Stancliff, Sharon
AU - Eldred, Lois
N1 - Funding Information:
Financial support. National Institute on Drug Abuse (grant K24 DA017072 to F.L.A. and Physician Scientist Award [grant K12 DA00167] to L.E.S.); Department of Health and Human Services Health Resources and Services Administration (grant H97HA03800 to F.L.A.); Substance Abuse and Mental Health Services Administration (grant H79 TI 15767 to F.L.A.); National Institutes of Health (Medical Scientist Training Program Grants at the Yale University School of Medicine to D.S.-R. and S.B.). L.E.S. is a Robert Wood Johnson Physician Faculty Scholar.
Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment,” sponsored by the National Institute on Drug Abuse, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Potential conflicts of interest. All authors: no conflicts.
PY - 2006/12/15
Y1 - 2006/12/15
N2 - Untreated opioid dependence is a major obstacle to the successful treatment and prevention of human immunodeficiency virus (HIV) infection. In this review, we examine the interwoven epidemics of HIV infection and opioid dependence and the emerging role of buprenorphine in improving HIV treatment outcomes among infected individuals, as well as its role in primary and secondary prevention. This article addresses some of the emerging issues about integrating buprenorphine treatment into HIV clinical care settings and the various strategies that must be considered. Specifically, it addresses the role of buprenorphine in improving HIV treatment outcomes through engagement in care, access to antiretroviral therapy and preventive therapies for opportunistic infections, and the potential benefits of and pitfalls in integrating buprenorphine into HIV clinical care settings. We discuss the key research questions regarding buprenorphine in the area of improving HIV treatment outcomes and prevention, including a review of published studies of buprenorphine and antiretroviral treatment and currently ongoing studies, and provide insight into and models for integrating buprenorphine into HIV clinical care settings. Dialogue among practitioners and policy makers in the HIV care and substance abuse communities will facilitate an effective expansion of buprenorphine and ensure that these beneficial outcomes are achieved.
AB - Untreated opioid dependence is a major obstacle to the successful treatment and prevention of human immunodeficiency virus (HIV) infection. In this review, we examine the interwoven epidemics of HIV infection and opioid dependence and the emerging role of buprenorphine in improving HIV treatment outcomes among infected individuals, as well as its role in primary and secondary prevention. This article addresses some of the emerging issues about integrating buprenorphine treatment into HIV clinical care settings and the various strategies that must be considered. Specifically, it addresses the role of buprenorphine in improving HIV treatment outcomes through engagement in care, access to antiretroviral therapy and preventive therapies for opportunistic infections, and the potential benefits of and pitfalls in integrating buprenorphine into HIV clinical care settings. We discuss the key research questions regarding buprenorphine in the area of improving HIV treatment outcomes and prevention, including a review of published studies of buprenorphine and antiretroviral treatment and currently ongoing studies, and provide insight into and models for integrating buprenorphine into HIV clinical care settings. Dialogue among practitioners and policy makers in the HIV care and substance abuse communities will facilitate an effective expansion of buprenorphine and ensure that these beneficial outcomes are achieved.
UR - http://www.scopus.com/inward/record.url?scp=33845403539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845403539&partnerID=8YFLogxK
U2 - 10.1086/508181
DO - 10.1086/508181
M3 - Review article
C2 - 17109304
AN - SCOPUS:33845403539
SN - 1058-4838
VL - 43
SP - S178-S183
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 4
ER -